Skip to main content
AAPL+0.11%NVDA+1.04%MSFT+0.14%GOOGL+0.78%AMZN+0.26%TSM+6.33%SPCX+8.62%META+0.27%TSLA+0.40%AVGO+0.74%LLY-0.79%BRK-B-0.25%WMT-1.72%SKHY+2.78%JPM-0.84%V+0.01%MU+0.42%AMD+11.04%XOM+0.34%JNJ+1.43%MA-0.49%ASMLa+2.69%ABBV+1.07%0700.HK-0.26%1398.HK-0.16%COST-1.13%CVX-0.15%KO-0.06%PG-1.02%CSCO-1.95%0939.HK+0.14%UNH-0.40%ORCL+0.77%HD-1.85%BAC-0.68%GE+2.70%3988.HK+0.08%1816.HK+1.93%0857.HK-0.29%1288.HK+0.15%PM-1.80%NVS+0.38%0005.HK+0.61%INTC+7.71%HSBA.L-0.21%AZN-0.22%MS-0.55%SAPd-2.32%9988.HK-0.15%ORp-1.27%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURDKK0.00%EURUSD0.00%CHFJPY0.00%EURNZD0.00%EURJPY0.00%NZDMXN0.00%EURNOK0.00%GBPCHF0.00%EURCAD0.00%PLNJPY0.00%CHFNOK0.00%USDHKD0.00%USDZAR0.00%USDPLN0.00%AUDCHF0.00%CADJPY0.00%EURSEK0.00%GBPUSD0.00%GBPCAD0.00%USDDKK0.00%GBPAUD0.00%GBPNZD0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%GBPZAR0.00%NZDCAD0.00%GBPSGD0.00%EURPLN0.00%W10.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.31%ETHUSD+28.67%USDTUSD-0.02%XRPUSD+27.34%SOLUSD+32.69%TRXUSDT+0.23%ZECUSDT+2.95%DOGEUSD+31.80%XMRUSDT+0.47%LINKUSD+0.01%BCHUSDT-0.66%XLMUSD+0.39%UNIUSD+2.22%LTCUSD+27.23%SUIUSD+0.41%HBARUSDT+0.61%TONUSD+56.05%TAOUSDT+1.86%AAVEUSD+0.94%DOTUSDT+0.77%ICPUSDT+0.58%ONDOUSDT+1.15%ARBUSDT+6.42%WLDUSDT+2.43%INJUSDT-0.15%JUPUSDT-0.49%ATOMUSDT-2.22%STXUSDT-0.32%TIAUSDT+2.01%PYTHUSDT-2.59%FETUSDT+0.26%SEIUSDT+3.36%IMXUSDT+0.05%OPUSDT-0.05%GRTUSDT-0.99%POLUSDT-0.63%WIFUSDT-0.73%IOTAUSDT-0.59%AXSUSDT+2.09%EOSUSDT+1.11%FARTCOINUSDT+3.98%DYDXUSDT-0.42%GALAUSDT-0.50%ORDIUSDT+4.86%RONINUSDT+3.92%NOTUSDT+5.35%AAPL+0.11%NVDA+1.04%MSFT+0.14%GOOGL+0.78%AMZN+0.26%TSM+6.33%SPCX+8.62%META+0.27%TSLA+0.40%AVGO+0.74%LLY-0.79%BRK-B-0.25%WMT-1.72%SKHY+2.78%JPM-0.84%V+0.01%MU+0.42%AMD+11.04%XOM+0.34%JNJ+1.43%MA-0.49%ASMLa+2.69%ABBV+1.07%0700.HK-0.26%1398.HK-0.16%COST-1.13%CVX-0.15%KO-0.06%PG-1.02%CSCO-1.95%0939.HK+0.14%UNH-0.40%ORCL+0.77%HD-1.85%BAC-0.68%GE+2.70%3988.HK+0.08%1816.HK+1.93%0857.HK-0.29%1288.HK+0.15%PM-1.80%NVS+0.38%0005.HK+0.61%INTC+7.71%HSBA.L-0.21%AZN-0.22%MS-0.55%SAPd-2.32%9988.HK-0.15%ORp-1.27%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURDKK0.00%EURUSD0.00%CHFJPY0.00%EURNZD0.00%EURJPY0.00%NZDMXN0.00%EURNOK0.00%GBPCHF0.00%EURCAD0.00%PLNJPY0.00%CHFNOK0.00%USDHKD0.00%USDZAR0.00%USDPLN0.00%AUDCHF0.00%CADJPY0.00%EURSEK0.00%GBPUSD0.00%GBPCAD0.00%USDDKK0.00%GBPAUD0.00%GBPNZD0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%GBPZAR0.00%NZDCAD0.00%GBPSGD0.00%EURPLN0.00%W10.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.31%ETHUSD+28.67%USDTUSD-0.02%XRPUSD+27.34%SOLUSD+32.69%TRXUSDT+0.23%ZECUSDT+2.95%DOGEUSD+31.80%XMRUSDT+0.47%LINKUSD+0.01%BCHUSDT-0.66%XLMUSD+0.39%UNIUSD+2.22%LTCUSD+27.23%SUIUSD+0.41%HBARUSDT+0.61%TONUSD+56.05%TAOUSDT+1.86%AAVEUSD+0.94%DOTUSDT+0.77%ICPUSDT+0.58%ONDOUSDT+1.15%ARBUSDT+6.42%WLDUSDT+2.43%INJUSDT-0.15%JUPUSDT-0.49%ATOMUSDT-2.22%STXUSDT-0.32%TIAUSDT+2.01%PYTHUSDT-2.59%FETUSDT+0.26%SEIUSDT+3.36%IMXUSDT+0.05%OPUSDT-0.05%GRTUSDT-0.99%POLUSDT-0.63%WIFUSDT-0.73%IOTAUSDT-0.59%AXSUSDT+2.09%EOSUSDT+1.11%FARTCOINUSDT+3.98%DYDXUSDT-0.42%GALAUSDT-0.50%ORDIUSDT+4.86%RONINUSDT+3.92%NOTUSDT+5.35%
AP

Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ • Healthcare

$58.16
+$0.69 (+1.2%)
Market closed

Last close at November 6, 2026 at 21:00 UTC

Open$58.66
Day Range$57 - $58.71
Avg. Volume (3M)1.6M
Market Cap$8.2B
52 Week Range
$37.06$95.49
Next EarningsIn 5 daysNov 12, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$75.2M100%
Gross Profitminus cost of goods$75.2M100%

Fundamentals & Financials

Revenue (TTM)
$669.4M
Net Income (TTM)
-$319.9M
EPS (TTM)
-$2.24
ROA (TTM)
-15.15%
Current Ratio
5.9
Dividend Yield
0.33%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-63.3%Q1 2026$0.22
+14.7%Q2 2026-$0.93
-6.3%Q3 2026-$1.36
Next

Nov 12

in 5 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.3%

Arrowhead Pharmaceuticals’ fiscal third quarter of 2026 results, reported August 4, showed a sharp revenue increase year over year, but EPS trailed consensus. Revenue rose 171% to roughly $75.3 million (up from about $27.8 million a year ago), while the company posted a net loss of about $194.3 million, widening by 11% year over year from roughly $175.2 million. On the bottom line, EPS was -$1.36 versus a -$1.28 estimate, trailed by -6.3%, and compared with -$1.26 a year ago (down 8% year over year). Profitability remained negative, with an operating loss of roughly $170.1 million, even as gross profit matched revenue at about $75.3 million. The company also paid roughly $38.4 million in dividends during the quarter. Consensus for the next period calls for EPS of USD -1.52 on revenue of USD 71.8 million.

Next report — what to expect

Arrowhead Pharmaceuticals, Inc. (ARWR) reports earnings on November 24, 2026. Wall Street’s next-period consensus calls for EPS of -$1.518 on revenue of $61.2 million. For trailing context, revenue grew +171.0% year over year last quarter. ARWR has beaten EPS in 2 of 8 most recent quarters.

View full earnings history

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company that develops RNA interference medicines for complex diseases, with activity centered in the United States. In FY2025, the company recorded $829.4 million in revenue as it advanced a pipeline spanning liver, cardiometabolic, pulmonary, oncology, neuromuscular, inflammatory, and infectious-disease programs.

Name
Arrowhead Pharmaceuticals, Inc.
CEO
Christopher R. Anzalone
Industry
Healthcare
Year Founded
1989
Employees
711

Today's Snapshot

AI-generated

ARWR closed 1.2% higher at 58.16, while its sector was flat. Arrowhead Pharmaceuticals refinanced $400 million. Earnings are due from ARWR on 12 November.

Trading Volume

Below 10d avg (1.4M)

1.3M

vs S&P 500 Today

Outperforming Market

+0.82%

Updated: November 6, 2026 at 21:17 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
ARWR shows a alignment of price weakness against longer-term averages that supports the strong-sell designation. ADX in the mid-20s suggests a developing bearish trend, while momentum readings are muted to negative—RSI in the high 30s and a mildly negative MACD point to limited upside conviction. The market trades below most short- and long-term moving averages, including the 200-day level, yet on-balance volume shows a positive divergence, indicating some buying interest amid broadly lower prices. Volatility is moderate and the pivot is near the market. Technical takeaway: strong sell — price below key averages and trend bias favor sellers despite mixed volume signals.
All signals
  • EMA (5 indicators)$59.23 - $69.84
    Sell
  • RSI (14)39.65
    Neutral
  • Stochastic %K (14, 3, 3)49.15
    Neutral
  • MACD Level (12, 26)-1.91
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.